Concepedia

Andrew M. Griffin

AM

16

Publications

501

Citations

13

H-Index

1975

Active since

Affiliations

AstraZeneca (Canada)(Current)

Florey Institute of Neuroscience and Mental Health

Precision for Medicine (United States)

Praxis (United States)

AstraZeneca (United States)

Andrew M. Griffin is an author at AstraZeneca (Canada) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1975–2022

16

Publications

16

Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734

Chevaun D. Morrison-Smith, Tatiana M. Knox, Ivona Filic et al. · Molecular Cancer Therapeutics · 2020 · 83 citations · Full text

Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules

Tim Luker, Lilian Alcaraz, Kamaldeep K. Chohan et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 57 citations

, , +6

Preclinical Pharmacology of AZD2327: A Highly Selective Agonist of the δ-Opioid Receptor

Thomas J. Hudzik, Carla Maciag, Mark A. Smith et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 54 citations

Safety, Pharmacokinetics, and Pharmacodynamics Study in Healthy Subjects of Oral NEO6860, a Modality Selective Transient Receptor Potential Vanilloid Subtype 1 Antagonist

W. A. Brown, Richard L. Leff, Andrew M. Griffin et al. · Journal of Pain · 2017 · 48 citations

, , +6

Discovery of the First Orally Available, Selective K<sub>Na</sub>1.1 Inhibitor: <i>In Vitro</i> and <i>In Vivo</i> Activity of an Oxadiazole Series

Andrew M. Griffin, Kristopher M. Kahlig, Robert J. Hatch et al. · ACS Medicinal Chemistry Letters · 2021 · 48 citations · Full text

Rows per page

1–5 of 16